Pitfalls in the detection of CV2 (CRMP5) antibodies

J Neuroimmunol. 2016 Jan 15:290:80-3. doi: 10.1016/j.jneuroim.2015.11.009. Epub 2015 Dec 1.

Abstract

CV2 antibodies (CV2-ab) associate with paraneoplastic neurological syndromes (PNS) and small-cell lung cancer. This study was designed to assess the sensitivity of two widely used anti-CV2 commercial kits. Fifty three sera with CV2-ab identified by immunohistochemistry on paraformaldehyde-perfused rat brain were tested with two commercial immunoblot kits (Euroimmun AG, and Ravo Diagnostika) and 4 (7.5%) of them were negative with the commercial kits. The 4 samples were positive by immunofluorescence on HEK293 cells transfected with CRMP5 and immunoblot of these cells lysate. A few CV2-ab-positive sera may be missed by commercial immunoblots. Negative samples from patients with high suspicion for PNS should be tested by alternative methods.

Keywords: CV2 (CRMP5) antibodies; Cancer; Immunoblot; Paraneoplastic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoantibodies / blood*
  • Autoantibodies / immunology*
  • Fluorescent Antibody Technique, Direct / methods
  • Fluorescent Antibody Technique, Direct / standards
  • HEK293 Cells
  • Humans
  • Hydrolases
  • Immunoblotting / methods
  • Immunoblotting / standards
  • Male
  • Microtubule-Associated Proteins
  • Nerve Tissue Proteins / blood*
  • Nerve Tissue Proteins / immunology*
  • Rats
  • Rats, Sprague-Dawley
  • Retrospective Studies

Substances

  • Autoantibodies
  • Microtubule-Associated Proteins
  • Nerve Tissue Proteins
  • DPYSL5 protein, human
  • Hydrolases